Health Care [ 3/12 ] | Biotechnology [ 26/74 ]
NASDAQ | Common Stock
Veracyte, Inc. operates as a diagnostics company in the United States and internationally.
The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis.
It is also developing Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test.
The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008.
Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 6, 24 | 0.19 Increased by +146.34% | 0.03 Increased by +533.33% |
| Aug 6, 24 | 0.07 Increased by +158.33% | -0.02 Increased by +450.00% |
| May 7, 24 | -0.02 Increased by +81.82% | -0.16 Increased by +87.50% |
| Feb 22, 24 | -0.39 Decreased by -680.00% | -0.09 Decreased by -333.33% |
| Nov 7, 23 | -0.41 Decreased by -241.67% | -0.15 Decreased by -173.33% |
| Aug 8, 23 | -0.12 Increased by +7.69% | -0.15 Increased by +20.00% |
| May 4, 23 | -0.11 Increased by +45.00% | -0.13 Increased by +15.38% |
| Feb 22, 23 | -0.05 Increased by +66.67% | -0.15 Increased by +66.67% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 115.86 M Increased by +28.58% | 15.15 M Increased by +151.17% | Increased by +13.08% Increased by +139.80% |
| Jun 30, 24 | 114.43 M Increased by +26.69% | 5.73 M Increased by +168.25% | Increased by +5.01% Increased by +153.87% |
| Mar 31, 24 | 96.84 M Increased by +17.50% | -1.86 M Increased by +67.21% | Decreased by -1.92% Increased by +72.09% |
| Dec 31, 23 | 98.20 M Increased by +22.29% | -28.29 M Decreased by -636.03% | Decreased by -28.81% Decreased by -501.85% |
| Sep 30, 23 | 90.11 M Increased by +19.20% | -29.62 M Decreased by -239.54% | Decreased by -32.87% Decreased by -184.84% |
| Jun 30, 23 | 90.32 M Increased by +23.96% | -8.40 M Increased by +11.85% | Decreased by -9.30% Increased by +28.89% |
| Mar 31, 23 | 82.42 M Increased by +21.60% | -5.68 M Increased by +60.69% | Decreased by -6.90% Increased by +67.68% |
| Dec 31, 22 | 80.30 M Increased by +19.25% | -3.84 M Increased by +63.49% | Decreased by -4.79% Increased by +69.38% |